|
|
Value of quantitative susceptibility mapping in determination of cerebral iron deposition of Parkinson's disease |
HAN Xu1, CHEN Jie1, SUN Jian1, ZHANG Lvming2, GE Wei3, WANG Zhiqun1 |
1. Department of Radiology, 2. Department of Neurology, Aerospace Central Hospital, Beijing 100049, China; 3. Department of Radiology, the Sixth Hospital of Chengde, Chengde 067200, China |
|
|
Abstract Objective To determine iron deposition in gray matter nuclei of Parkinson's disease (PD) by quantitative magnetic sensitivity imaging (QSM) and its correlation with clinical conditions, and to explore its role in the pathogenesis of PD. Methods PD patients admitted to Beijing Aerospace Central Hospital from May 2023 to May 2024 were enrolled into PD group and normal control (NC) group with similar age and sex were chosen. PD patients and NC group were subjected to magnetic resonance imaging, and the final QSM magnetic sensitive value (MSV) parameter graph was obtained by Matlab post-processing software. The MSV of caudate nucleus, lenticular nucleus, red nucleus, substantia nigra and dentate nucleus were measured. PD group was divided into mild disease group (Hoehn-Yahr stage≤2.5) and moderate-severe disease group (Hoehn-Yahr stage≥3.0) according to Hoehn-Yahr stage. According to part 3 of unified Parkinson's disease rating scale (UPDRS-Ⅲ), the patients were divided into low and high score groups. The differences of nuclear MSV values between different groups and their correlation with clinical conditions were compared. Results There were statistically significant differences in MSV values of multiple nuclear masses between PD groups, PD scoring groups and NC group (P<0.05). The MSV values of substantia nigra and dentate nucleus were higher, and the differences between the groups were statistically significant (P<0.05). There was correlation between the MSV values of substantia nigra and dentate nucleus and UPDRS-Ⅲ score in PD moderate-severe disease group (P<0.05). Conclusions QSM can reflect the content of iron deposition in gray matter nuclei of PD patients, and become an important imaging biomarker to evaluate the occurrence and development of PD. The content of iron deposition in substantia nigra and dentate nucleus can best reflect the severity of PD, especially the motor symptoms.
|
Received: 08 October 2024
|
|
|
|
|
[1] |
中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第四版)[J].中华神经科杂志,2020,53(12):973-986.
|
[2] |
David S G,Yehonatan S.The heart of PD: lewy body diseases as neurocardiologic disorders[J].Brain Res,2019, 1702:74-84.
|
[3] |
Chen Q,Chen Y,Zhang Y,et al.Iron deposition in Parkinson's disease by quantitative susceptibility mapping[J]. BMC Neurosci,2019,20(1):23.
|
[4] |
Duan M,Pan R,Gao Q,et al.A rapid multi-parametric quantitative MR imaging method to assess Parkinson's disease: a feasibility study[J]. BMC Med Imaging,2024,24(1): 58.
|
[5] |
Schaffner S L,Casazza W,Artaud F,et al.Genetic variation and pesticide exposure influence blood DNA methylation signatures in females with early-stage Parkinson's disease[J].NPJ Parkinsons Dis,2024,10(1): 98.
|
[6] |
倪民桦,李泽阳,谢 昊, 等.QSM对无轻度认知功能障碍的2型糖尿病病人脑内铁沉积的评估[J].国际医学放射学杂志,2023,46(1):5-9.
|
[7] |
Kao Y R,Chen J,Kumari R,et al. An iron rheostat controls hematopoietic stem cell fate[J].Cell Stem Cell,2024, 31(3):378-397.
|
[8] |
Kroneberg D,Fatly B,Morkos C,et al.Kinematic effects of combined subthalamic and dorsolateral nigral deep brain stimulation in Parkinson's disease[J].J Parkinsons Dis,2024,14(2):269-282.
|
[9] |
Lakhani D A,Zhou X,Tao S,et al.Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson's disease[J].NPJ Parkinsons Dis,2024,10(1):13.
|
[10] |
Seo K,Matunari I,Yamamoto T.Cerebral cortical thinning in Parkinson's disease depends on the age of onset[J]. PLoS One,2023,18(2):e0281987.
|
[11] |
冷一峻,刘学玲,刘丰韬,等.基于多模态MRI的帕金森病及其亚型脑微结构异常模式研究及鉴别[J].中国临床神经科学,2022,30(2):129-136,152.
|
[12] |
陈宇昆,王学廉.弥散张量成像追踪齿状核-红核-丘脑束在脑深部电刺激治疗帕金森病震颤症状的应用[J]. 中国微侵袭神经外科学杂志,2018,23(5):193-196.
|
[13] |
Xu W,Zhi Y,Yuan Y,et al.Correlations between abnormal iron metabolism and non-motor symptoms in Parkinson's disease[J].J Neural Transm(Vienna),2018,125(7):1027-1032.
|
|
|
|